Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare today presented positive findings from the CUSTOMIZE trial
-
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
Data to be presented underscore the commitment to developing innovative treatment and prevention options
-
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease
Full results to be presented at a medical meeting later this year
-
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases
-
Elliott Advisors (UK) letter to GSK
The Board of GSK notes the letter issued by Elliott Advisors (UK) Limited (“Elliott”) on 1 July
-
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline
New GSK to positively impact health of >2.5 billion people next 10 years
-
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
Halozyme's technology provides more "shots on goal" to create ultra long-acting HIV medicines with dosing intervals of 3 months or longer
-
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab.
-
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies
-
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
-
GSK to showcase scientific advances and progress in oncology at ASCO and EHA
GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.
-
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
-
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA
-
GSK announced as a Principal Partner of COP26 UN Climate Change Conference
As Principal Partner, GSK will drive action on climate, nature and health targets in support of COP26 ambitions.
-
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
Neutralizing antibody responses were ten times higher than in people recovering from COVID-19.
-
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups.
-
GSK Consumer Healthcare commits to make over a billion toothpaste tubes recyclable by 2025 as part of its ongoing sustainability journey
GSKCH’s initiatives support GSK’s company wide commitment to achieve a net zero impact on climate and a positive impact on nature by 2030.
-
GSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19
Review will support a formal Marketing Authorisation Application.
-
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
The rolling submission allows ViiV Healthcare to submit portions of the regulatory application to the FDA as they are completed.
-
GSK students take on the role of engineers during GSK Science in the Summer™ in partnership with The Franklin Institute
GSK students take on the role of engineers during GSK Science in the Summer™ in partnership with The Franklin Institute.
